Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Harvard Bioscience (HBIO) Common Equity (2016 - 2025)

Historic Common Equity for Harvard Bioscience (HBIO) over the last 17 years, with Q3 2025 value amounting to $14.1 million.

  • Harvard Bioscience's Common Equity fell 7846.36% to $14.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $14.1 million, marking a year-over-year decrease of 7846.36%. This contributed to the annual value of $63.3 million for FY2024, which is 1332.07% down from last year.
  • According to the latest figures from Q3 2025, Harvard Bioscience's Common Equity is $14.1 million, which was down 7846.36% from $15.7 million recorded in Q2 2025.
  • In the past 5 years, Harvard Bioscience's Common Equity registered a high of $83.4 million during Q4 2021, and its lowest value of $14.1 million during Q3 2025.
  • In the last 5 years, Harvard Bioscience's Common Equity had a median value of $73.1 million in 2023 and averaged $64.2 million.
  • Per our database at Business Quant, Harvard Bioscience's Common Equity surged by 876.36% in 2021 and then crashed by 7846.36% in 2025.
  • Over the past 5 years, Harvard Bioscience's Common Equity (Quarter) stood at $83.4 million in 2021, then fell by 13.41% to $72.2 million in 2022, then rose by 1.18% to $73.1 million in 2023, then decreased by 13.32% to $63.3 million in 2024, then tumbled by 77.79% to $14.1 million in 2025.
  • Its Common Equity stands at $14.1 million for Q3 2025, versus $15.7 million for Q2 2025 and $14.8 million for Q1 2025.